Advertisement

Topics

AstraZeneca, MedImmune, Ethris to develop mRNA therapies for respiratory diseases

02:05 EDT 22 Aug 2017 | Pharmaceutical Business Review

AstraZeneca and its research and development arm MedImmune have entered into five-year strategic research collaboration with Ethris to develop mRNA therapies for respiratory diseases.

Original Article: AstraZeneca, MedImmune, Ethris to develop mRNA therapies for respiratory diseases

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca, MedImmune, Ethris to develop mRNA therapies for respiratory diseases"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...